Author

Emmanuel Raffoux

Medical Doctor, Hopital Saint Louis, Paris - Cited by 17,617 - H

Biography

 Emmanuel Raffoux is  working  at Adolescents and Yound Adult Hematology unit In Saint Louis Hospital, Paris at France. International experience includes various programs, contributions and participation in different countries for diverse fields of study and interests reflect in wide range of publications in various national and international journals
Title
Cited by
Year
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy
R Itzykson, E Fournier, C Berthon, C Röllig, T Braun, A Marceau-Renaut, ...Blood, The Journal of the American Society of Hematology 138 (7), 507-519, 2021202
35
2021
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study
M Duchmann, JB Micol, N Duployez, E Raffoux, X Thomas, JP Marolleau, ...Blood, The Journal of the American Society of Hematology 137 (20), 2827-2837, 2021202
33
2021
Actinomycin D targets NPM1c-primed mitochondria to restore PML-driven senescence in AML therapy
HC Wu, D Rérolle, C Berthier, R Hleihel, T Sakamoto, S Quentin, ...Cancer discovery 11 (12), 3198-13, 2021202
32
2021
Long term follow-up and combined phase 2 results of eprenetapopt (APR-246) and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic …
DA Sallman, RS Komrokji, AE DeZern, M Sebert, G Garcia-Manero, ...Blood 138, 246, 202
21
2021
Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms
C Marcault, LP Zhao, N Maslah, E Verger, R Daltro de Oliveira, ...Blood, The Journal of the American Society of Hematology 138 (21), 2142-2148, 2021202
19
2021
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a …
R Benjamin, N Jain, MV Maus, N Boissel, C Graham, A Jozwik, D Yallop, ...The Lancet Haematology 9 (11), e833-e843, 2022202
17
2022
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia
B Pardieu, J Pasanisi, F Ling, R Dal Bello, J Penneroux, A Su, ...Leukemia 36 (6), 85-95, 2022202
15
2022
The omission of high-dose cytarabine during consolidation therapy of Ph-positive ALL patients treated with nilotinib and low-intensity chemotherapy results in an increased risk …
P Rousselot, Y Chalandon, S Chevret, JM Cayuela, F Huguet, ...Blood 138, 512, 2021202
14
2021
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study
S Kayser, RF Schlenk, D Lebon, M Carre, KS Götze, F Stölzel, ...haematologica 106 (), 3100, 2021202
12
2021
Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
J Lambert, J Lambert, X Thomas, A Marceau-Renaut, JB Micol, ...Blood Advances 5 (23), 5258-5268, 2021202
11
2021
Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia
C Pautas, E Raffoux, J Lambert, O Legrand, S Chantepie, L Gastaud, ...Bone Marrow Transplantation 56 (6), 1474-1477, 2021202
10
2021
Fractionated inotuzumab ozogamicin combined with low-intensity chemotherapy provides very good outcome in older patients with newly diagnosed CD22+ Philadelphia chromosome …
P Chevallier, T Leguay, M Doubek, F Huguet, C Salek, A Cabannes, ...Blood 138, 511, 2021202
10
2021
Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia
M Sebert, S Gachet, T Leblanc, A Rousseau, O Bluteau, R Kim, ...Cell stem cell 30 (2), 153-170. e, 2023202
9
2023
A 2: 1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia
K Sweet, B Bhatnagar, H Döhner, W Donnellan, O Frankfurt, M Heuser, ...Leukemia & Lymphoma 62 (13), 3192-3203, 2021202
7
2021
A multiparametric niche-like drug screening platform in acute myeloid leukemia
R Dal Bello, J Pasanisi, R Joudinaud, M Duchmann, B Pardieu, P Ayaka, ...Blood Cancer Journal 12 (6), 9, 2022202
5
2022
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use
A Lesieur, X Thomas, O Nibourel, N Boissel, L Fenwarth, S De Botton, ...haematologica 106 (6), 1767, 2021202
5
2021
Biological effects of BET inhibition by OTX015 (MK-8628) and JQ1 in NPM1-mutated (NPM1c) acute myeloid leukemia (AML)
Biological effects of BET inhibition by OTX01 (MK-8628) and JQ1 in NPM1-mutated (NPM1c) acute myeloid leukemia (AML)H Djamai, J Berrou, M Dupont, MM Coudé, M Delord, E Clappier, ...Biomedicines 9 (11), 1704, 2021202
5
2021
Antifungal Prophylaxis in AML patients receiving intensive induction chemotherapy: a prospective observational study from the acute leukaemia french association (ALFA) group
M Michallet, M Sobh, S Morisset, A Deloire, E Raffoux, S de Botton, ...Clinical Lymphoma Myeloma and Leukemia 22 (5), 311-318, 20224202
4
2022
Hepatosplenic candidiasis in patients with hematological malignancies: A 13-year retrospective cohort study
Hepatosplenic candidiasis in patients with hematological malignancies: A 1-year retrospective cohort studyI Boussen, Q Lisan, E Raffoux, R Di Blasi, N Boissel, E Oksenhendler, ...Open Forum Infectious Diseases 9 (4), ofac088, 2022202
3
2022
Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation
AS Del Galy, A Rousseau, A Capes, D Michonneau, M Robin, ...Bone Marrow Transplantation 57 (9), 165-172, 2022202
3
2022

Referred From: https://scholar.google.fr/citations?user=oNPszKcAAAAJ&hl=fr

Cited by
Citations 17617
h-index 70
i10-index 198
Recommended Journals
Open Access Journals